Company / Cash & Equivalents
Progyny Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$112.2M
FY2025
5-year range
$91.4M / $162.3M
FY2021-FY2025
Trend
-30.9%
vs FY2024
Sector context
#108 of 152
Health Care
What the data says
At $112M, Progyny's cash & equivalents ranks #108 of 152 in the Health Care sector. Cash & Equivalents has fluctuated over the past 8 years, ranging from $127,000 in FY2018 to $162M in FY2024.
Based on SEC 10-K filings.
$112M in FY2025 with a 5-year CAGR of +9.8%.
Improved from $97M to $112M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -2.2%
- 5-Year CAGR
- +9.8%
- 10-Year CAGR
- -
Sector benchmark
#108 of 152 in Health CareTop 71% of 152This company $112.2M Sector average $1.2B
▼
-90.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +9.8%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 30.9% year-over-year.
- Ranks #108 out of 152 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 3.62 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.2M | -30.9% |
| FY2024 | $162.3M | +66.8% |
| FY2023 | $97.3M | -19.0% |
| FY2022 | $120.1M | +31.4% |
| FY2021 | $91.4M | +30.0% |
| FY2020 | $70.3M | -12.5% |
| FY2019 | $80.4M | +63192.9% |
| FY2018 | $127.0K | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026